ArticleACS biomaterials science & engineering2016
Photothermal therapy of glioblastoma multiforme using multiwalled carbon nanotubes optimized for diffusion in extracellular space.
Article in ACS biomaterials science & engineering, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 84 citations in OpenAlex.
- Small Particles, Big Impact: Inorganic Nanotechnology for Glioblastoma.Molecules (Basel, Switzerland) · 2026Review
- Safety and Potential Neuromodulatory Effects of Multi-Wall Carbon Nanotubes in Vertebrate and Invertebrate Animal Models In Vivo.International journal of molecular sciences · 2025Article
- Nanostructured lipid carriers for enhanced batimastat delivery across the blood-brain barrier: an in vitro study for glioblastoma treatment.Drug delivery and translational research · 2025Article
- Engineering Tumor-Specific Nanotheranostic Agent with MR Image-Guided NIR-II & -III Photodynamic Therapy to Combat Against Deeply Seated Orthotopic Glioblastoma.Small science · 2024Article
- Enhancing in vitro photothermal therapy using plasmonic gold nanorod decorated multiwalled carbon nanotubes.Biomedical optics express · 2023Article
- Graphene-Based Nanomaterials for Photothermal Therapy in Cancer Treatment.Pharmaceutics · 2023Review
- Challenges and advances for glioma therapy based on inorganic nanoparticles.Materials today. Bio · 2023Review
- Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Nanotechnology-Based Combinatorial Anti-Glioblastoma Therapies: Moving from Terminal to Treatable.Pharmaceutics · 2022Review
- Gold and Carbon-Based Nano-theranostics: An Overview on the Developments and Applications for Cancer Phototherapy.Advanced pharmaceutical bulletin · 2022Review
- Metal-Based Nanostructured Therapeutic Strategies for Glioblastoma Treatment-An Update.Biomedicines · 2022Review
- Article
- Review
- Perspective of mesenchymal transformation in glioblastoma.Acta neuropathologica communications · 2021Review
- Dendrimer-based nanohybrids in cancer photomedicine.Materials today. Bio · 2021Review
- Carbon Nanotubes: Smart Drug/Gene Delivery Carriers.International journal of nanomedicine · 2021Review
- Hyperthermia treatment advances for brain tumors.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2020Review
- Nano-Therapies for Glioblastoma Treatment.Cancers · 2020Review
- Photothermal Therapy for the Treatment of Glioblastoma: Potential and Preclinical Challenges.Frontiers in oncology · 2020Review
- NDs@PDA@ICG Conjugates for Photothermal Therapy of Glioblastoma Multiforme.Biomimetics (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma multiforme (GBM) is the most common and most lethal primary brain tumor with a 5 year overall survival rate of approximately 5%. Currently, no therapy is curative and all have significant side effects. Focal thermal ablative therapies are being investigated as a new therapeutic approach. Such therapies can be enhanced using nanotechnology. Carbon nanotube mediated thermal therapy (CNMTT) uses lasers that emit near infrared radiation to excite carbon nanotubes (CNTs) localized to the tumor to generate heat needed for thermal ablation. Clinical translation of CNMTT for GBM will require development of effective strategies to deliver CNTs to tumors, clear structure-activity and structure-toxicity evaluation, and an understanding of the effects of inherent and acquired thermotolerance on the efficacy of treatment. In our studies, we show that a dense coating of phospholipid-poly(ethylene glycol) on multiwalled CNTs (MWCNTS) allows for better diffusion through brain phantoms, while maintaining the ability to achieve ablative temperatures after laser exposure. Phospholipid-poly(ethylene glycol) coated MWCNTs do not induce a heat shock response (HSR) in GBM cell lines. Activation of the HSR in GBM cells via exposure to sub-ablative temperatures or short term treatment with an inhibitor of heat shock protein 90 (17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG)), induces a protective heat shock response that results in thermotolerance and protects against CNMTT. Finally, we evaluate the potential for CNMTT to treat GBM multicellular spheroids. These data provide pre-clinical insight into key parameters needed for translation of CNMTT including nanoparticle delivery, cytotoxicity, and efficacy for treatment of thermotolerant GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.